Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide

• Published in: Journal of allergy and clinical immunology Vol. 92; no. 6; pp. 891 - 901
• Main Authors: Hassner, Avi, Lau, Matthew S., Goetzl, Edward J., Adelman, Daniel C.
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.12.1993; Elsevier
• Subjects: Analysis of the immune response. Humoral and cellular immunity; B-Lymphocyte Subsets - cytology; B-Lymphocyte Subsets - drug effects; B-Lymphocyte Subsets - immunology; Biological and medical sciences; Cell Division - drug effects; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Humans; Immunobiology; Immunoglobulin A - biosynthesis; Immunoglobulin E - biosynthesis; Immunoglobulin G - biosynthesis; immunoglobulin isotype regulation; Immunoglobulin Isotypes - biosynthesis; Immunoglobulin M - biosynthesis; In Vitro Techniques; Interleukin-4 - pharmacology; Lymphocytes - cytology; Lymphocytes - drug effects; Lymphocytes - immunology; Miscellaneous; neuropeptides; Regulatory factors and their cellular receptors; T-Lymphocyte Subsets - cytology; T-Lymphocyte Subsets - drug effects; T-Lymphocyte Subsets - immunology; Vasoactive intestinal peptide; Vasoactive Intestinal Peptide - pharmacology; IL; Vasoactive intestinal peptide; PWM; neuropeptides; cAMP; VIP; immunoglobulin isotype regulation; PBMCs; Human; Immunoglobulins; Gastrointestinal hormone; Leukocyte; Peptide hormone; Isotype; Immune regulation; Neuropeptide; In vitro; Lymphocyte
• ISSN: 0091-6749
• DOI: 10.1016/0091-6749(93)90067-P

Exposure of lymphocytes to nanomolar to micromolar concentrations of vasoactive intestinal peptide (VIP) for 1 to 3 days only modestly suppressed or enhanced the production of IgA and IgM, but not IgG. The effects of twice daily additions of 10 −12 to 10 −7 mol/L VIP for up to 18 days on pokeweed mitogen- stimulated peripheral blood mononuclear cells (PBMCs) from normal human subjects was examined by quantifying the production of IgG, IgM, and IgA. The maximum suppression of IgG by 10 −9 mol/L VIP was 79% ± 33% (mean ± SD) (range, 41 % to 97%; p < 0.015) on day 9 and 84% ± 1 % (range, 74% to 96%; p < 0.0001) on day 14 and was significant at 6 × 10 −10 to 4 × 10 −9 mol/L VIP. Suppression of IgM production by 10 −9 mol/L VIP was significant and was observed first on day 5 and persisted through day 14. VIP did not alter IgA production or affect the proliferation or viability of PBMCs. The production of IgE by interleukin-4 stimulated PBMCs was enhanced consistently in two subjects but not in two other subjects. The duration of exposure to nanomolar concentrations of VIP is thus a critical determinant of its immunoregulatory effect, as manifested by late suppression of production of IgG and IgM and concurrent enhancement of production of IgE in some subjects.